ATE482712T1 - Überstände von mesenchymstammzellen zur vorbeugung und behandlung von immunantworten in transplantationen - Google Patents

Überstände von mesenchymstammzellen zur vorbeugung und behandlung von immunantworten in transplantationen

Info

Publication number
ATE482712T1
ATE482712T1 AT00974007T AT00974007T ATE482712T1 AT E482712 T1 ATE482712 T1 AT E482712T1 AT 00974007 T AT00974007 T AT 00974007T AT 00974007 T AT00974007 T AT 00974007T AT E482712 T1 ATE482712 T1 AT E482712T1
Authority
AT
Austria
Prior art keywords
mesenchymal stem
immune response
transplantations
preventing
stem cell
Prior art date
Application number
AT00974007T
Other languages
German (de)
English (en)
Inventor
Kevin Mcintosh
Joseph Mosca
Elena Klyushenkova
Original Assignee
Osiris Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osiris Therapeutics Inc filed Critical Osiris Therapeutics Inc
Application granted granted Critical
Publication of ATE482712T1 publication Critical patent/ATE482712T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1352—Mesenchymal stem cells
    • C12N2502/1358—Bone marrow mesenchymal stem cells (BM-MSC)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT00974007T 1999-10-26 2000-10-26 Überstände von mesenchymstammzellen zur vorbeugung und behandlung von immunantworten in transplantationen ATE482712T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/427,333 US6368636B1 (en) 1998-03-18 1999-10-26 Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
PCT/US2000/029815 WO2001032189A1 (en) 1999-10-26 2000-10-26 Supernatant from mesenchymal stem cells for prevention and treatment of immune responses in transplantation

Publications (1)

Publication Number Publication Date
ATE482712T1 true ATE482712T1 (de) 2010-10-15

Family

ID=23694416

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00974007T ATE482712T1 (de) 1999-10-26 2000-10-26 Überstände von mesenchymstammzellen zur vorbeugung und behandlung von immunantworten in transplantationen

Country Status (10)

Country Link
US (2) US6368636B1 (enExample)
EP (2) EP1223956B1 (enExample)
JP (1) JP2004506598A (enExample)
AT (1) ATE482712T1 (enExample)
AU (1) AU782064B2 (enExample)
CA (1) CA2387542C (enExample)
DE (1) DE60045034D1 (enExample)
ES (1) ES2351203T3 (enExample)
PT (1) PT1223956E (enExample)
WO (1) WO2001032189A1 (enExample)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1062321B1 (en) * 1998-03-13 2004-12-29 Osiris Therapeutics, Inc. Uses for humane non-autologous mesenchymal stem cells
US20040265285A1 (en) * 1999-04-15 2004-12-30 Monash University Normalization of defective T cell responsiveness through manipulation of thymic regeneration
US20050042679A1 (en) * 1999-04-15 2005-02-24 Monash University Diagnostic indicator of thymic function
AU2003901668A0 (en) * 2003-03-28 2003-05-01 Medvet Science Pty. Ltd. Non-haemopoietic precursor cells
AUPQ147799A0 (en) * 1999-07-07 1999-07-29 Medvet Science Pty. Ltd. Mesenchymal precursor cell
US20050158289A1 (en) * 1999-07-07 2005-07-21 Simmons Paul J. Mesenchymal precursor cell and use thereof in the repair of bone defects and fractures in mammals
US8062675B2 (en) 1999-07-07 2011-11-22 Angioblast Systems, Inc. Mesenchymal precursor cell
US7670628B2 (en) * 1999-07-07 2010-03-02 Angioblast Systems, Inc. Mesenchymal precursor cell
US8147824B2 (en) 1999-08-05 2012-04-03 Athersys, Inc. Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
ATE460475T1 (de) * 2000-04-11 2010-03-15 Univ Southern California Methode zur verhinderung der transplantatabstossung unter verwendung von tgf- beta zur induktion von t-suppressorzellen
US20060088512A1 (en) * 2001-10-15 2006-04-27 Monash University Treatment of T cell disorders
JP2004521877A (ja) * 2000-11-22 2004-07-22 ジェロン コーポレイション 多能性幹細胞の同種移植片の寛容化
US20080152629A1 (en) * 2000-12-06 2008-06-26 James Edinger Placental stem cell populations
WO2002046373A1 (en) * 2000-12-06 2002-06-13 Hariri Robert J Method of collecting placental stem cells
US7311905B2 (en) 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
NZ528035A (en) * 2001-02-14 2005-07-29 Robert J Hariri Renovation and repopulation of decellularized tissues and cadaveric organs by stem cells
NZ527849A (en) * 2001-02-14 2006-09-29 Anthrogenesis Corp Post-partum mammalian placenta, its use and placental stem cells therefrom
WO2003024462A1 (en) * 2001-09-19 2003-03-27 Henry Ford Health System Cardiac transplantation of stem cells for the treatment of heart failure
JP2005531507A (ja) * 2002-03-02 2005-10-20 ザ ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム ストローマ細胞前駆体による抗癌物質の局所的な産生および／または送達方法
AU2003240512B2 (en) * 2002-06-04 2009-11-05 The Board Of Trustees Of The Leland Stanford Junior University Device and method for rapid aspiration and collection of body tissue from within an enclosed body space
AU2003295444A1 (en) * 2002-11-15 2004-06-15 The Board Of Trustees Of The University Of Illinois Methods for in vitro expansion of hematopoietic stem cells
US20040101959A1 (en) * 2002-11-21 2004-05-27 Olga Marko Treatment of tissue with undifferentiated mesenchymal cells
AU2003289907A1 (en) * 2002-11-28 2004-06-18 Genethor Gmbh Cells not presenting antigen for suppressing pathological immune reactions
CA2521217C (en) * 2003-04-01 2013-05-14 United States Of America Department Of Veteran's Affairs Stem-cell, precursor cell, or target cell-based treatment of multi-organ failure and renal dysfunction
GB0321337D0 (en) * 2003-09-11 2003-10-15 Massone Mobile Advertising Sys Method and system for distributing advertisements
US20080279812A1 (en) * 2003-12-05 2008-11-13 Norwood Immunology, Ltd. Disease Prevention and Vaccination Prior to Thymic Reactivation
CA2934682C (en) * 2004-03-22 2021-12-07 Mesoblast International Sarl Mesenchymal stem cells and uses therefor
EP2298861B1 (en) 2004-03-22 2017-09-13 Mesoblast International Sàrl Mesenchymal stem cells and uses therefor
US7622108B2 (en) * 2004-04-23 2009-11-24 Bioe, Inc. Multi-lineage progenitor cells
ATE506431T1 (de) * 2004-04-23 2011-05-15 Bioe Llc Mehrfachlinien-vorläuferzellen
WO2005113751A1 (en) * 2004-05-14 2005-12-01 Becton, Dickinson And Company Cell culture environments for the serum-free expansion of mesenchymal stem cells
CA2504451A1 (en) * 2004-08-10 2006-02-10 Geron Corporation Dendritic cell vaccines for treating cancer made from embryonic stem cells
US20060045872A1 (en) 2004-08-25 2006-03-02 Universidad Autonoma De Madrid Ciudad Universitaria de Cantoblanco Use of adipose tissue-derived stromal stem cells in treating fistula
WO2006031539A2 (en) * 2004-09-10 2006-03-23 Cognate Therapeutics, Inc. Liver stromal cells for prevention and treatment of immune responses in transplantation
AU2005287855B2 (en) * 2004-09-24 2011-06-16 Mesoblast, Inc. Method of enhancing proliferation and/or survival of mesenchymal precursor cells (MPC)
CA2512667A1 (en) * 2005-01-07 2006-07-07 Takahiro Ochiya Human hepatocyte-like cells and uses thereof
EP1841322A4 (en) * 2005-01-11 2009-12-09 Cognate Therapeutics Inc BONE MARROW BINDING WEB CELLS FOR IMMUNE PROTECTION OF TRANSPLANTED NEURAL STEM CELLS
US20080241112A1 (en) * 2005-05-10 2008-10-02 Christof Westenfelder Therapy of Kidney Diseases and Multiorgan Failure with Mesenchymal Stem Cells and Mesenchymal Stem Cell Conditioned Media
JP5925408B2 (ja) * 2005-09-23 2016-05-25 タイジェニックス、ソシエダッド、アノニマ、ウニペルソナルＴｉｇｅｎｉｘ Ｓ．Ａ．Ｕ． 免疫調節活性を有する細胞集団、単離方法および使用
US20070082328A1 (en) * 2005-09-27 2007-04-12 Donnie Rudd Rotatable time varying electromagnetic force bioreactor and method of using the same
NZ597304A (en) 2005-10-13 2013-06-28 Anthrogenesis Corp Immunomodulation using placental stem cells
US11000546B2 (en) 2005-11-09 2021-05-11 Athersys, Inc. Immunomodulatory properties of MAPCs and uses thereof
US10117900B2 (en) 2005-11-09 2018-11-06 Athersys, Inc. MAPC treatment of brain injuries and diseases
JP2009521930A (ja) 2005-12-29 2009-06-11 アントフロゲネシス コーポレーション 胎盤幹細胞及び第２供給源由来幹細胞の共存培養
DK2471904T3 (en) * 2005-12-29 2019-02-18 Celularity Inc Placenta stem cell populations
ES2415855T3 (es) 2006-01-13 2013-07-29 Osiris Therapeutics, Inc. Células troncales mesenquimatosas que expresan el receptor de TNF
US11992507B2 (en) 2006-01-23 2024-05-28 Abt Holding Company MAPC therapeutics without adjunctive immunosuppressive treatment
US7727763B2 (en) * 2006-04-17 2010-06-01 Bioe, Llc Differentiation of multi-lineage progenitor cells to respiratory epithelial cells
WO2007143139A1 (en) 2006-05-31 2007-12-13 The Brigham And Women's Hospital, Inc. Abcb5 positive mesenchymal stem cells as immunomodulators
MX2008015645A (es) * 2006-06-09 2009-02-06 Anthrogenesis Corp Nicho placentario y uso de este para cultivar celulas primordiales.
US7993918B2 (en) * 2006-08-04 2011-08-09 Anthrogenesis Corporation Tumor suppression using placental stem cells
EP2054506A1 (en) * 2006-08-15 2009-05-06 Agency for Science, Technology and Research Mesenchymal stem cell conditioned medium
JP5537153B2 (ja) 2006-11-03 2014-07-02 アストロム バイオサイエンシーズ， インコーポレイテッド 組織修復のための混合細胞集団および細胞処理のための単離技術
HRP20130765T1 (hr) 2007-02-12 2013-10-25 Anthrogenesis Corporation Lijeäśenje protuupalnih bolesti putem matiäśnih stanica posteljice
EP2607477B1 (en) 2007-05-03 2020-09-23 The Brigham and Women's Hospital, Inc. Multipotent stem cells and uses thereof
TWM322542U (en) * 2007-05-23 2007-11-21 Universal Scient Ind Co Ltd Testing machine
EA201070022A1 (ru) * 2007-06-15 2010-06-30 Гарнет Байотерапьютикс Инк. Лечение заболеваний и нарушений с использованием самообновляющихся образующих колонии клеток, культивированных и размноженных in vitro
CN101835479A (zh) * 2007-07-25 2010-09-15 佰欧益有限公司 多系祖细胞分化为软骨细胞
AU2008307633C1 (en) 2007-09-28 2015-04-30 Celularity Inc. Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
JP5539886B2 (ja) * 2007-10-17 2014-07-02 ティクセル Ｔｒ１細胞、間葉系幹細胞およびその使用
US9011840B2 (en) * 2008-03-14 2015-04-21 The Board Of Trustees Of The University Of Illinois Activated mesenchymal stem cells for wound healing and impaired tissue regeneration
WO2009114860A2 (en) * 2008-03-14 2009-09-17 The Board Of Trustees Of The University Of Illinois Activated mesenchymal stem cells for the prevention and repair of inflammatory states
US20110150845A1 (en) * 2008-05-02 2011-06-23 Massachusetts Institute Of Technology Methods and compositions for modulating immunological tolerance
WO2009143241A2 (en) * 2008-05-21 2009-11-26 Bioe, Inc. Differentiation of multi-lineage progenitor cells to pancreatic cells
JP5950577B2 (ja) * 2008-08-20 2016-07-13 アンスロジェネシス コーポレーション 単離胎盤細胞を使用した脳卒中の治療
MX339624B (es) 2008-08-20 2016-06-02 Anthrogenesis Corp Composiciones mejoradas de celulas y metodos para preparar las mismas.
EP2331109B1 (en) 2008-08-22 2013-05-29 Anthrogenesis Corporation Methods and compositions for treatment of bone defects with placental cell populations
US11542328B2 (en) 2008-11-14 2023-01-03 The Brigham And Women's Hospital, Inc. Therapeutic and diagnostic methods relating to cancer stem cells
ES2796111T3 (es) 2008-11-14 2020-11-25 Brigham & Womens Hospital Inc Métodos terapéuticos relacionados con células madre cancerosas
CA2743566C (en) * 2008-11-19 2021-11-09 Anthrogenesis Corporation Amnion derived adherent cells
WO2010060031A1 (en) * 2008-11-21 2010-05-27 Anthrogenesis Corporation Treatment of diseases, disorders or conditions of the lung using placental cells
US9301975B2 (en) 2009-05-01 2016-04-05 Biocardia, Inc. Method of preparing autologous cells and method of use for therapy
AU2010276201B2 (en) * 2009-07-21 2013-10-17 Healios K.K. Use of stem cells to reduce leukocyte extravasation
DK3284818T3 (da) * 2010-01-26 2022-06-20 Celularity Inc Behandling af knoglerelateret kræft ved hjælp af placenta stamceller
TW201703777A (zh) 2010-04-07 2017-02-01 安瑟吉納西斯公司 利用胎盤幹細胞之血管新生
NZ602798A (en) 2010-04-08 2014-10-31 Anthrogenesis Corp Treatment of sarcoidosis using placental stem cells
KR101203954B1 (ko) 2010-04-15 2012-11-22 서울대학교산학협력단 혈관 내피 세포성 중간엽 줄기세포를 포함하는 면역 조절용 조성물
SG10201913920PA (en) 2010-05-12 2020-03-30 Abt Holding Co Modulation of splenocytes in cell therapy
WO2012009422A1 (en) 2010-07-13 2012-01-19 Anthrogenesis Corporation Methods of generating natural killer cells
US20120087868A1 (en) 2010-10-08 2012-04-12 Gabriele Todd Nanoparticle-loaded cells
WO2012048298A2 (en) 2010-10-08 2012-04-12 Caridianbct, Inc. Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions
AR093183A1 (es) 2010-12-31 2015-05-27 Anthrogenesis Corp Aumento de la potencia de celulas madre de placenta usando moleculas de arn moduladoras
CN104220081A (zh) 2011-06-01 2014-12-17 人类起源公司 利用胎盘干细胞治疗疼痛
WO2013055476A1 (en) 2011-09-09 2013-04-18 Anthrogenesis Corporation Treatment of amyotrophic lateral sclerosis using placental stem cells
KR20140096105A (ko) * 2011-11-04 2014-08-04 더 텍사스 에이 & 엠 유니버시티 시스템 중간엽 줄기 세포 및/또는 ｔｓｇ-6 단백질에 의한 이식 거부의 예방 및 치료
WO2014123879A1 (en) 2013-02-05 2014-08-14 Anthrogenesis Corporation Natural killer cells from placenta
US9801912B2 (en) 2013-02-19 2017-10-31 Va Boston Healthcare System ABCB5(+) stem cells for treating ocular disease
AU2014250761B2 (en) 2013-04-12 2019-02-28 Robert J. Deans Improving organs for transplantation
BR112015028193B8 (pt) 2013-05-10 2023-04-18 Childrens Medical Center Suporte para cicatrização de feridas
EP3662915B1 (en) * 2013-05-22 2023-02-22 National Center of Neurology and Psychiatry Mesenchymal stem cells and immunogens for use in inducing acquired immunological tolerance
KR101723265B1 (ko) 2013-08-16 2017-04-04 가톨릭대학교 산학협력단 mTOR/STAT3 신호억제제 처리된 면역조절능을 갖는 간엽줄기세포 및 이를 포함하는 면역질환의 예방 또는 치료용 세포치료제 조성물
WO2015023147A1 (ko) * 2013-08-16 2015-02-19 가톨릭대학교 산학협력단 mTOR/STAT3 신호억제제 처리된 면역조절능을 갖는 간엽 줄기세포 및 이를 포함하는 면역질환의 예방 또는 치료용 세포치료제 조성물
WO2015073918A1 (en) 2013-11-16 2015-05-21 Terumo Bct, Inc. Expanding cells in a bioreactor
US11008547B2 (en) 2014-03-25 2021-05-18 Terumo Bct, Inc. Passive replacement of media
WO2016049421A1 (en) 2014-09-26 2016-03-31 Terumo Bct, Inc. Scheduled feed
RU2644650C2 (ru) 2014-12-01 2018-02-13 Общество с ограниченной ответственностью "Т-Хелпер Клеточные Технологии" Материал стволовых клеток и способ его получения
US20160287752A1 (en) * 2014-12-31 2016-10-06 Applied Biologics, Llc Reconstituted amniotic membrane-amniotic fluid combination tissue graft with standardized stem cell component and method of forming same
CN113106053A (zh) * 2015-04-21 2021-07-13 恩立夫克治疗有限责任公司 治疗性汇集的血液凋亡细胞制剂与其用途
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
US11389141B2 (en) 2016-02-01 2022-07-19 RegenMed Systems, Inc. Cannula for tissue disruption
GB201604304D0 (en) 2016-03-14 2016-04-27 Tigenix S A U Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in crohn's disease
US11965175B2 (en) 2016-05-25 2024-04-23 Terumo Bct, Inc. Cell expansion
RU2708329C2 (ru) 2016-05-31 2019-12-05 Общество с ограниченной ответственностью "Т-Хелпер Клеточные Технологии" Материал стволовых клеток, композиции и способы применения
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US12234441B2 (en) 2017-03-31 2025-02-25 Terumo Bct, Inc. Cell expansion
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
US11629332B2 (en) 2017-03-31 2023-04-18 Terumo Bct, Inc. Cell expansion
WO2018227363A1 (zh) * 2017-06-13 2018-12-20 广州赛莱拉干细胞科技股份有限公司 一种防治糖尿病足的干细胞组合物及其应用、干细胞制剂
CN112004923A (zh) 2017-11-22 2020-11-27 迈索布拉斯特国际有限公司 细胞组合物及治疗方法
KR20210005118A (ko) 2018-04-25 2021-01-13 칠드런'즈 메디컬 센터 코포레이션 Abcb5 리간드 및 기질
GB2619893A (en) 2021-03-23 2023-12-20 Terumo Bct Inc Cell capture and expansion
US12209689B2 (en) 2022-02-28 2025-01-28 Terumo Kabushiki Kaisha Multiple-tube pinch valve assembly
PT118103A (pt) 2022-07-13 2024-01-15 Univ Aveiro Biomaterial para imunomodulação, processo de produção e suas aplicações
USD1099116S1 (en) 2022-09-01 2025-10-21 Terumo Bct, Inc. Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5733542A (en) * 1990-11-16 1998-03-31 Haynesworth; Stephen E. Enhancing bone marrow engraftment using MSCS
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5591625A (en) 1993-11-24 1997-01-07 Case Western Reserve University Transduced mesenchymal stem cells
US6797269B2 (en) * 1998-04-03 2004-09-28 Osiris Therapeutics, Inc. Mesenchymal stem cells as immunosuppressants
US6685936B2 (en) * 1999-10-12 2004-02-03 Osiris Therapeutics, Inc. Suppressor cells induced by culture with mesenchymal stem cells for treatment of immune responses in transplantation
CA2490682A1 (en) 2004-12-16 2006-06-16 Ibm Canada Limited - Ibm Canada Limitee Method and system for advanced downloadings of urls for web navigation
TW200819387A (en) 2006-10-19 2008-05-01 Univ Yuan Ze Micro-reacting device having a micro-channel flow-guiding block

Also Published As

Publication number Publication date
EP1223956B1 (en) 2010-09-29
AU782064B2 (en) 2005-06-30
CA2387542A1 (en) 2001-05-10
CA2387542C (en) 2012-01-24
AU1244501A (en) 2001-05-14
EP2269616A3 (en) 2012-06-27
DE60045034D1 (de) 2010-11-11
WO2001032189A1 (en) 2001-05-10
ES2351203T3 (es) 2011-02-01
US6875430B2 (en) 2005-04-05
EP2269616A2 (en) 2011-01-05
EP1223956A1 (en) 2002-07-24
US6368636B1 (en) 2002-04-09
PT1223956E (pt) 2010-12-06
US20020085996A1 (en) 2002-07-04
JP2004506598A (ja) 2004-03-04
WO2001032189A9 (en) 2002-07-04

Similar Documents

Publication Publication Date Title
ATE482712T1 (de) Überstände von mesenchymstammzellen zur vorbeugung und behandlung von immunantworten in transplantationen
ATE319312T1 (de) Suppressorzellen zur prävention und behandlung von immunantworten bei transplantationen
ATE316795T1 (de) Mesenchymale stammzellen für die prävention und behandlung von immunantworten bei transplantationen
ES2180653T3 (es) Tratamiento de material biologico antes de la implantacion.
DE69827001D1 (de) Gewebedezellularization
DE69837491D1 (de) Menschliche mesenchymale stammzellen aus peripherem blut
ATE265191T1 (de) Herstellungsverfahren von gewebe zur implantation
DE69941903D1 (de) Behandlung von patienten die eine knochenmarktransplantation oder eine transplantation peripherer blutstammzellen erhalten mit anti-cd20 antikörpern
NO963742L (no) Fremgangsmåte til å stimulere hematopoese med hemaglobin
DE69525151D1 (de) Methoden zur krankheitsbehandlung unter verwendung von sertoli-zellen und allotransplantat oder xenotransplantat
WO2007070301A3 (en) Vascular graft sterilization and decellularization
DE69829202D1 (de) Verwendung von mirtazapine zur herstellung eines medikaments zur behandlung von schlafapnoen
DK1150698T3 (da) Anvendelser af vaskulær endotelvækstfaktor i behandlingen af erektil dysfunktion
ATE297217T1 (de) Zusammensetzung zur vorbeugung und behandlung von transplantatabstossung
BR0107544A (pt) Composição de promoção de secreção de bile
DE69937892D1 (de) Implantatmaterial
GB2400556B (en) Therapeutic composition for autoimmune conditions
NO20054912L (no) Behandling av aspergillus infeksjoner med tymosin alfa 1
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
TW200621986A (en) Liver stromal cells for prevention and treatment of immune responses in transplantation
NO20022109D0 (no) Anvendelse av treosulfan for behandling av pasienter för benmargs- eller blodstamcelletansplantasjon
CA3253257A1 (en) USE OF A PROBIOTIC COMPOSITION IN A PROCESS FOR TREATMENT OF MANIFESTATIONS OF SELF-REPORTED MENTAL EXHAUSTION, PREFERABLY WITH MANIFESTATIONS OF LOW ENERGY LEVELS
RU2002117852A (ru) Способ лечения больных псориазом в сочетании с хроническим описторхозом
UA69988A (en) Method for treating complicated choledocholithiasis
ATE419843T1 (de) Methode zur in vitro reduzierung von durch freie radikale induzierte schäden

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties